ALX-0651 is a dual-complementarity-determining region humanized monoclonal antibody inhibitor targeting CXCR4. It can inhibit the transport of hematopoietic stem cells as well as the progression and metastasis of tumors. ALX-0651 is applicable for research in treating non-Hodgkins lymphoma and multiple myeloma.
Target-Kategorie:
CXCR
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
